EXPRESSION OF ONCOGENES IN LYMPHOPROLIFERATIVE DISORDERS

我们继续研究了bcl-2在卵巢上皮细胞中的表达， 淋巴瘤和霍奇金病。我们开发了一种分离 RNA，然后逆转录和PCR扩增。使用此 程序，我们能够测量bcl-2的表达水平， 活检标本。在滤泡性淋巴瘤的情况下，我们有一个小系列， 发现表达水平与预后有很强的相关性; 然而，在得出最后结论之前，必须对更多的案例进行研究 可以画出来。研究表明，bcl-2可能导致生长优势， 但其他癌基因，特别是myc的参与是必要的， 达到完全的恶性潜能因此，我们正在研究 同一滤泡性淋巴瘤中myc mRNA的表达水平 使用我们开发的技术。因为点突变导致 活性增加的蛋白质可能与RNA水平一样重要，我们 也在寻找肿瘤标本中myc基因的突变。这 将提供重要的信息，以相互关系的各种 滤泡性淋巴瘤的发病机制 我们已经证明32%的人存在t（14;18）易位 霍奇金淋巴瘤。然而，霍奇金病和滤泡性淋巴瘤是 两个不同的临床病理实体我们亦会研究 bcl-2/JH转录本和bcl-2蛋白产物在 霍奇金病患者，并再次将这些信息与 临床过程这一数据将提供有关 bcl-2在造血系统恶性肿瘤中的作用

We have continued in our studies of the expression of bcl-2 in follicular lymphoma and Hodgkin's disease. We developed a procedure for isolation of RNA followed by reverse transcription and PCR amplification. Using this procedure, we are able to measure the levels of expression of bcl-2 in biopsy specimens. In a small series of follicular lymphoma cases, we have found the levels of expression to have a strong correlation with prognosis; however, a greater number of cases must be studied before final conclusions can be drawn. Studies indicate that bcl-2 may incur a growth advantage to cells but that involvement of other oncogenes, especially myc, is necessary to attain full malignant potential. We thus are undertaking a study of levels of expression of myc m-RNA in these same follicular lymphoma specimens using a technique we have developed. As point mutations leading to a protein of increased activity may be as important as levels of RNA, we are also looking for mutations in the myc gene in tumor specimens. This will provide important information as to the interrelationship of various oncogenes in the development of follicular lymphoma. We have demonstrated the t(14;18) translocation to be present in 32% of Hodgkin's lymphomas. However, Hodgkin's disease and follicular lymphoma are two distinct clinical-pathological entities. We shall also examine the expression of the bcl-2/JH transcript and of the bcl-2 protein product in Hodgkin's disease patients and again correlate this information with the clinical course. This data will provide further information concerning the role of bcl-2 in hematopoietic malignancies.